Clinical trials and other studies in which low disease activity or remission has been used as an end
Remission as the treatment goal – the FIN-RACo trial
T. Sokka, H. Mäkinen, K. Puolakka, T. Möttönen, P. Hannonen
CER2876
2006 Vol.24, N°6 ,Suppl.43
PI 0074, PF 0076
Clinical trials and other studies in which low disease activity or remission has been used as an end
Free to view
(click on article PDF icon to read the article)
PMID: 17083766 [PubMed]
Abstract
ABSTRACT: The Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial is the first rheumatoid arthritis (RA) clinical trial in which remission served as the primary outcome measure. This chapter reviews the philosophical background, study design, and results of the FIN-RACo trial. The study showed that a third of patients with active early RA may achieve remission with a combination of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and prednisolone.
